Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention [Online]. 2012 Dec (update). Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf [last accessed Sep 2013]
   Google Scholar
• Martínez-Moratalla J, Almar E, Sunyer J, Ramos J, Pereira A, Payo F. European asthma study. Identifying and treating young adults with epidemiological criteria for asthma in five areas of Spain. Spanish Group of the European Asthma Study. Arch Bronconeumol 1999;35:223–228
   PubMedGoogle Scholar
• García-Marcos L, Quirós AB, Hernández GG, Guillén-Grima F, Díaz CG, Ureña IC, et al. Stabilization of asthma prevalence among adolescents and increase among schoolchildren (ISAAC phases I and III) in Spain. Allergy 2004;59:1301–1307
   PubMed Web of Science ®Google Scholar
• The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Resp J 2003;22:470–477
   PubMed Web of Science ®Google Scholar
• Xolair®. Ficha Técnica del medicamento. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Propietary Medicinal Products (CPMP). European Public Assesment Report (EPAR): Xolair®. Available from: http://www.ema.europa.eu. Last Accessed January 2014
   Google Scholar
• Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573–582
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184–190
   PubMed Web of Science ®Google Scholar
• Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 2012;49:144–152
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–316
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302–308
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bouquet J, et al. Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632–638
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154–159
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world' effectiveness of omalizumab in allergic asthma. Respir Med 2013;107:1141–1151
   PubMed Web of Science ®Google Scholar
• Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A, Niven R. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma 2013;50:529–536
   PubMed Web of Science ®Google Scholar
• Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, Rottbauer W, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2012;6:215–227
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009;103:1633–1642
   PubMed Web of Science ®Google Scholar
• Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009;103:1725–1731
   PubMed Web of Science ®Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, Caiaffa MF, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104:1410–1416
   PubMed Web of Science ®Google Scholar
• Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, Buhl R. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010;105:313–319
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, Molimard M, et al. Pharmacoepidemiology of Asthma and Xolair (PAX) Study Group. Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest 2013;143:398–405
   PubMed Web of Science ®Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit 2010;24:154–170
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012;49:843–848
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201) [Online]. 2013 Apr. Available at: http://www.nice.org.uk/nicemedia/live/14157/63689/63689.pdf. [last accessed Sep 2013]
   Google Scholar
• Dewilde S, Turk F, Tambour M, Sandström T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765–1776
   PubMed Web of Science ®Google Scholar
• Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007:120:1146–1152
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32–38
   PubMed Web of Science ®Google Scholar
• Comité Ejecutivo GEMA 2009. Guía española del manejo del asma. Arch Bronconeumol 2009:45:2–35
   Google Scholar
• Dilla T, González de Dios J, Sacristán JA. Evaluación Económica en Medicina (I): fundamentos y Metodología. Evid Pediatr 2009;5:71
   Google Scholar
• Chen H, Gould MK, Blanc PD, Miller DP, Kamath TV, Lee JH, Sullivan SD. TENOR Study Group. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol 2007;120:396–402
   PubMed Web of Science ®Google Scholar
• CGCOF. Consejo General del Colegio Oficial de Farmacéuticos. Base de datos del medicamento [Online]. 2012. Available from: http://www.portalfarma.com [last accessed Dec 2012]
   Google Scholar
• R Core Team. 2013. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing
   Google Scholar
• Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002;16:334–343
   PubMedGoogle Scholar
• van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ 2013;16:342–348
   PubMedGoogle Scholar
• Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011;43:45–53
   PubMedGoogle Scholar
• Watson L, Turk F, James P, Holgate ST. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med 2007;101:1659–1664
   PubMed Web of Science ®Google Scholar
• Löwhagen O, Ekström L, Holmberg S, Wennerblom B, Rosenfeldt M. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243–247
   PubMed Web of Science ®Google Scholar